Questions & Answers About Clinical Trials

Our latest podcast features Robert Miller of the National Fragile X Foundation and representatives of the the major pharmaceutical companies involved in ongoing Fragile X Clinical Trials. We have Dr. Paul Wang, Vice President, Clinical Development of Seaside Therapeutics; Dr. Eriene Wasef, Associate Clinical Director of Hoffman-La Roche; and Dr. Marla Hochfeld, Executive Medical Director of Novartis. Listeners will hear insightful answers to the following questions:

What is a clinical trial?
Why are clinical trials important?
How do clinical trials contribute to the safety of new drugs?
How do clinical trials contribute to the usefulness of new drugs?
What should I expect to be told about a trial and what should I not expect to be able to know?
Can I drop out of a trial at any time?
What about other medications my child might be taking?
Can my child stay on the trial drug when a trial ends and, if not, why not?
When a trial ends, should I expect to be contacted about the results or will I need to find that out on my own?
What is the best way for listeners to learn about your company’s specific trial or trials?

The NFXF encourages you to view our newest site feature, a state-by-state listing of clinical trials being conducted of potential new drugs for the treatment of fragile X syndrome and see if one might be right for you.